Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Lerodalcibep · 1 trial · 1 indication
The primary objective of this study is to assess the change in LDL-C (by Friedewald Formula) at Week 156 with monthly lerodalcibep 300 mg QM
| Arm | Type | Description |
|---|---|---|
| Lerodalcibep | EXPERIMENTAL | lerodalcibep 300 mg monthly |
| Name | Type | Description |
|---|---|---|
| Lerodalcibep | DRUG | 300 mg monthly |
Inclusion Criteria: 1. Provision of written and signed informed consent/assent of the LIB003-016 trial prior to any study-specific procedure; 2. Completion of the LIB003-008 study having received the last dose of study drug at Week 20 and completed the Week 24 visit; 3. Male or female, 6 to 17 year...